Hikma Labs Inc. Sustainability Profile
Hikma Labs Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2007, the company has established itself as a leader in the development and manufacturing of high-quality generic and specialty medications. Hikma Labs is renowned for its innovative approach to drug formulation, focusing on complex generics and injectables that address critical healthcare needs. Their commitment to quality and compliance has earned them a strong market position, with notable achievements in regulatory approvals and product launches. With a diverse portfolio of core products, Hikma Labs continues to enhance patient care through accessible and effective therapeutic solutions, solidifying its reputation as a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Hikma Labs Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hikma Labs Inc.'s score of 48 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hikma Labs Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Hikma Pharmaceuticals PLC, which may influence its climate commitments and emissions reporting. As of now, there are no documented reduction targets or climate pledges directly associated with Hikma Labs Inc. However, emissions data and performance metrics may be inherited from its parent company, Hikma Pharmaceuticals PLC, which operates under a broader corporate sustainability framework. This cascading of data occurs at a level 2 relationship, indicating that while Hikma Labs Inc. may not have its own specific targets, it aligns with the sustainability initiatives of its parent organisation. Hikma Pharmaceuticals PLC has been involved in various climate initiatives, including participation in the CDP (formerly Carbon Disclosure Project), which may provide insights into the broader emissions strategies and commitments of the corporate family. However, specific figures or targets from these initiatives have not been detailed for Hikma Labs Inc. itself. In summary, while Hikma Labs Inc. does not currently report its own emissions or reduction targets, it is part of a corporate structure that may influence its climate commitments through the practices and policies of Hikma Pharmaceuticals PLC.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 16,817,000 | - | - | 00,000,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 49,779,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
How Carbon Intensive is Hikma Labs Inc.'s Industry?
How Carbon Intensive is Hikma Labs Inc.'s Location?
Hikma Labs Inc.'s Scope 3 Categories Breakdown
Hikma Labs Inc.'s Scope 3 emissions, which decreased by 95% last year and decreased by approximately 94% since 2021, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 26% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 1599% of Scope 3 emissions.
Top Scope 3 Categories
Hikma Labs Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hikma Labs Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
